‘Very rare’ risk of Guillain–Barre syndrome after Shingrix vaccination: TGA
The regulator said the vaccine was not generally recommended for patients with a history of the syndrome.
Recombinant herpes zoster vaccine Shingrix carries a “very rare” risk of Guillain–Barre syndrome, the TGA says.
The regulator says patients should be advised to seek medical care if they have symptoms such as paraesthesia, numbness or paralysis post-vaccination.
